Table 1

Clinical and biochemical characteristics before and after intervention in the weight loss and ezetimibe plus weight loss groups

Weight lossEzetimibe plus weight loss
022 weeks022 weeks
n1015
Body weight (kg)100 ± 694 ± 5*94 ± 387 ± 3*
BMI (kg/m2)33 ± 131 ± 1*32 ± 131 ± 1*
Waist (cm)107 ± 498 ± 4*106 ± 296 ± 2*
Total fat mass (kg)39 ± 435 ± 4*37 ± 332 ± 3*
Fat-free mass (kg)60 ± 359 ± 356 ± 355 ± 3
Visceral fat at L3 vertebra (cm2)278 ± 38228 ± 36257 ± 25213 ± 22*
Subcutaneous fat at L3 vertebra (cm2)358 ± 43316 ± 36278 ± 30257 ± 28
Intrahepatic triglyceride content (%)22 ± 516 ± 4*18 ± 310 ± 2*
Alanine aminotransferase (U/l)32 ± 526 ± 429 ± 230 ± 3
Cholesterol (mmol/l)5.8 ± 0.25.5 ± 0.25.8 ± 0.34.9 ± 0.3*
Triglyceride (mmol/l)1.7 ± 0.31.3 ± 0.22.0 ± 0.21.5 ± 0.1*
Nonesterified fatty acids (mEq/l)0.62 ± 0.070.56 ± 0.060.74 ± 0.110.75 ± 0.10
HDL cholesterol (mmol/l)1.3 ± 0.21.3 ± 0.11.1 ± 0.11.1 ± 0.1
LDL cholesterol (mmol/l)3.7 ± 0.23.7 ± 0.23.8 ± 0.33.1 ± 0.2*
Lathosterol (μmol/l)12 ± 110 ± 2*12 ± 115 ± 2
Campesterol (μmol/l)5.4 ± 0.94.9 ± 0.79.1 ± 1.53.2 ± 0.5*
ApoA-I (g/l)1.5 ± 0.11.5 ± 0.11.4 ± 0.11.4 ± 0.1
ApoB-100 (g/l)1.2 ± 0.11.1 ± 0.11.2 ± 0.10.9 ± 0.1*
ApoC-III (mg/l)176 ± 15153 ± 16*186 ± 12160 ± 13*
Glucose (mmol/l)5.5 ± 0.25.7 ± 0.25.5 ± 0.25.6 ± 0.1
Insulin (mU/l)12 ± 210 ± 212 ± 19 ± 1
HOMA score3.1 ± 0.52.6 ± 0.42.9 ± 0.32.2 ± 0.3
  • Data are means ± SEM. There was no significant group difference in the variables at baseline.

  • *P < 0.01, value significantly different from baseline value.

  • P < 0.05.

  • P< 0.05, value significantly different using general linear modeling after adjustment for relative changes in the weight loss group.